For example, copper depletion exhibits promising efficacy in pre‐clinical animal models and in a phase I clinical trial,34 and ferumoxytol displays anti‐leukemia efficacy against cells with low ferroportin levels.35 Copper chelating agents and ferumoxytol also show anti‐lung cancer activity in preclinical studies.36, 37 We showed that the concentrations of 14 elements were increased or decreased in lung tumor tissues compared to their counterpart normal lung tissues, suggesting that normalization of these elements may have therapeutic potentials for NSCLCs. Here, SLC40A1 is linked to leukemia.